MÃœNCHEN, GERMANY--(MARKET WIRE)--Jun 15, 2006 -- Carlsbad, CA - June 15, 2006 - Micromet, Inc. (NasdaqNM:MITI - News), a transatlantic biopharmaceutical company focused on the development of antibody-based drugs, reports results of a scientific study1 published in Molecular Immunology. The study describes one of the first human, high-affinity IgG1 antibodies potently neutralizing human GM-CSF. The compound, designated MT203, was generated by Micromet using phage display-guided selection and is currently in preclinical development as a novel treatment for inflammatory and autoimmune diseases including but not limited to rheumatoid arthritis (RA), asthma, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS) and psoriasis.
